Improving equity in access to early diagnosis of cancer in different healthcare systems of Latin America: protocol for the EquityCancer-LA implementation-effectiveness hybrid study.
adult oncology
change management
health policy
medical education & training
organisation of health services
quality in health care
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
13 12 2022
13 12 2022
Historique:
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
Healthcare fragmentation, a main cause for delay in cancer diagnosis and treatment, contributes to high mortality in Latin America (LA), particularly among disadvantaged populations. This research focuses on integrated care interventions, which have been limitedly implemented in the region. The objective is to evaluate the contextual effectiveness of scaling-up an integrated care intervention to improve early diagnosis of frequent cancers in healthcare networks of Chile, Colombia and Ecuador. This research is two pronged: (A) quasi-experimental design (controlled before and after) with an intervention and a control healthcare network in each LA country, using an implementation-effectiveness hybrid approach to assess the intervention process, effectiveness and costs; and (B) case study design to analyse access to diagnosis of most frequent cancers. Focusing on the most vulnerable socioeconomic population, it develops in four phases: (1) analysis of delays and barriers to early diagnosis (baseline); (2) intervention adaptation and implementation (primary care training, fast-track referral pathway and patient information); (3) intracountry evaluation of intervention and (4) cross-country analysis. Baseline and evaluation studies adopt mixed-methods qualitative (semistructured individual interviews) and quantitative (patient questionnaire survey) methods. For the latter, a sample size of 174 patients with cancer diagnosis per healthcare network and year was calculated to detect a proportions difference of 15%, before and after intervention (α=0.05; β=0.2) in a two-sided test. A participatory approach will be used to tailor the intervention to each context, led by a local steering committee (professionals, managers, policy makers, patients and researchers). This study complies with international and national legal stipulations on ethics. It was approved by each country's ethical committee and informed consent will be obtained from participants. Besides the coproduction of knowledge with key stakeholders, it will be disseminated through strategies such as policy briefs, workshops, e-tools and scientific papers.
Identifiants
pubmed: 36523219
pii: bmjopen-2022-067439
doi: 10.1136/bmjopen-2022-067439
pmc: PMC9748968
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e067439Investigateurs
M L Vazquez
(ML)
Aida Oliver
(A)
Verónica Espinel
(V)
Zahara Fernández
(Z)
Josep Maria Borràs
(JM)
Montserrat Gil-Girbau
(M)
Antoni Serrano-Blanco
(A)
Paula Arroyo-Uriarte
(P)
María Luisa Garmendia
(ML)
Ana María Oyarce
(AM)
Camilo Bass
(C)
Isabel Guzmán
(I)
Andrea Alvarez
(A)
Paola González
(P)
Isabel Abarca
(I)
Rodney Stock
(R)
Berta Cerda
(B)
Guillermo Hartwig
(G)
Cristopher Tabilo
(C)
Carmen Aravena
(C)
Gloria Stephens
(G)
Virginia Garcia
(V)
Ana Maria Pedraza
(AM)
Angela Pinzón
(A)
Carol Cardozo
(C)
María Camila Rangel
(MC)
Pablo Cristancho
(P)
William Mantilla
(W)
Guillermo León
(G)
Juan Merchán
(J)
Iván Dueñas
(I)
Hugo Pereira
(H)
Daniel Ruiz
(D)
Estefanía Rodríguez
(E)
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Int J Nurs Stud. 2011 Feb;48(2):258-68
pubmed: 21030021
Cancer Rep (Hoboken). 2022 Sep;5(9):e1564
pubmed: 34725973
Cad Saude Publica. 2018 Jun 21;34(6):e00074817
pubmed: 29947654
Lancet. 2015 Mar 28;385(9974):1230-47
pubmed: 25458725
J Health Serv Res Policy. 2012 Apr;17(2):110-8
pubmed: 22008712
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Br J Cancer. 2009 Dec 3;101 Suppl 2:S5-8
pubmed: 19956163
Rev Med Chil. 2017 Dec;145(12):1507-1513
pubmed: 29652946
Colomb Med (Cali). 2018 Mar 30;49(1):89-96
pubmed: 29983468
BMJ. 2000 Sep 16;321(7262):694-6
pubmed: 10987780
Aust J Rural Health. 2012 Oct;20(5):259-64
pubmed: 22998200
Lancet Oncol. 2015 Sep;16(12):1231-72
pubmed: 26431866
Evid Rep Technol Assess (Summ). 2004 Aug;(99):1-8
pubmed: 15460504
Implement Sci. 2018 Dec 27;13(1):154
pubmed: 30587195
Ecancermedicalscience. 2019 Jan 22;13:897
pubmed: 30792814
BMJ Open. 2015 Jul 31;5(7):e007037
pubmed: 26231753
Nat Rev Clin Oncol. 2016 Dec;13(12):740-749
pubmed: 27458007
Med Care. 1981 Dec;19(12 Suppl):4-27
pubmed: 7339313
J Oncol Pract. 2006 Sep;2(5):228-30
pubmed: 20859340
J Telemed Telecare. 1998;4(2):113-9
pubmed: 9744168
PLoS One. 2019 Oct 16;14(10):e0224012
pubmed: 31618268
Health Technol Assess. 2001;5(23):iii-157
pubmed: 11785749
Health Serv Res. 1974 Fall;9(3):208-20
pubmed: 4436074
BMJ. 1997 Aug 16;315(7105):418-21
pubmed: 9277610
Telemed J. 2000 Summer;6(2):213-8
pubmed: 10957733
Br J Gen Pract. 2011 Dec;61(593):e821-35
pubmed: 22137419
Health Serv Res. 2003 Apr;38(2):751-76
pubmed: 12785571
Br J Cancer. 2011 Sep 6;105(6):753-9
pubmed: 21829194
J Health Soc Behav. 1995 Mar;36(1):1-10
pubmed: 7738325
Oncologist. 2019 Dec;24(12):e1371-e1380
pubmed: 31387949
Educ Prim Care. 2013 Jul;24(4):274-90
pubmed: 23906171
Implement Sci. 2011 Oct 06;6:116
pubmed: 21974914
Cancer Manag Res. 2021 Jul 29;13:5875-5887
pubmed: 34349561
Med Care. 2008 Jul;46(7):647-53
pubmed: 18580382
J Gastrointest Cancer. 2021 Nov 29;:
pubmed: 34843058
BMJ. 2007 Mar 3;334(7591):455-9
pubmed: 17332585
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Am J Community Psychol. 2008 Jun;41(3-4):327-50
pubmed: 18322790
Fam Pract. 2017 Apr 1;34(2):154-160
pubmed: 28207044
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Br J Cancer. 2015 Mar 31;112 Suppl 1:S57-64
pubmed: 25734381
Einstein (Sao Paulo). 2016 Jul-Sep;14(3):330-337
pubmed: 27759820
BMJ. 2021 Sep 30;374:n2061
pubmed: 34593508
BMC Fam Pract. 2016 Jul 26;17:95
pubmed: 27460041
Nat Rev Clin Oncol. 2014 Jan;11(1):38-48
pubmed: 24247164
Lancet Oncol. 2013 Apr;14(5):391-436
pubmed: 23628188
Br J Cancer. 2014 Feb 4;110(3):584-92
pubmed: 24366304
Lancet Oncol. 2017 Oct;18(10):e607-e617
pubmed: 28971827
Adv Ther. 2019 Jan;36(1):19-30
pubmed: 30499068
Milbank Q. 2004;82(4):581-629
pubmed: 15595944
BMC Cancer. 2014 Aug 30;14:636
pubmed: 25175155
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
Br J Cancer. 2012 Mar 27;106(7):1262-7
pubmed: 22415239
J Eval Clin Pract. 2000 Nov;6(4):337-43
pubmed: 11133117
Lancet Oncol. 2020 Jun;21(6):748-750
pubmed: 32359404
World J Clin Oncol. 2014 Aug 10;5(3):465-77
pubmed: 25114860
Adm Policy Ment Health. 2011 Jan;38(1):44-53
pubmed: 20967495
Med Etika Bioet. 2002 Spring-Summer;9(1-2):12-9
pubmed: 16276663
Health Res Policy Syst. 2018 Jul 11;16(1):60
pubmed: 29996848
Health Policy Plan. 2020 Oct 1;35(8):962-972
pubmed: 32743666
J Glob Oncol. 2019 Jul;5:1-9
pubmed: 31260395
Salud Publica Mex. 2011 Nov-Dec;53(6):478-85
pubmed: 22282140
Cad Saude Publica. 2018 Jun 25;34(6):e00046317
pubmed: 29952397